Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI to predict cancer risk from gut bacteria and scans

NCT ID NCT07605312

Knowledge-focused Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will collect data from 10,000 people undergoing upper endoscopy to build an AI model that predicts the risk of developing stomach or esophageal cancer. Researchers will combine information from endoscopy images, tissue samples, genetics, and gut bacteria. Participants will be followed over time to see who develops cancer or precancerous changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a reliable AI tool that helps doctors identify people at high risk for stomach or esophageal cancer earlier, potentially improving screening and prevention.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not prove accurate enough for real-world use, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Patients with a history of surgery involving the esophagus, stomach, or duodenum. * Patients with gastric deformity secondary to severe gastric inflammation. * Patients unable to undergo regular follow-up upper gastrointestinal endoscopy every 1-3 years. * Patients with severe comorbidities that preclude follow-up upper gastrointestinal endoscopy or with an estimated life expectancy of less than 10 years.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing upper gastrointestinal endoscopy. * Patients with at least one of the following conditions or indications: * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test); * Dyspeptic symptoms; * Gastroesophageal reflux disease; * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma; * Barrett's esophagus; * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis); * Gastric subepithelial lesions. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic gastritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Barrett esophagus chronic atrophic gastritis dyspepsia esophageal cancer Esophageal Neoplasms gastric cancer gastric intestinal metaplasia gastric neoplasm gastroesophageal reflux disease Helicobacter pylori infectious disease hypopharynx squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma preneoplastic lesion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic gastritis Dysplasia stomach Esophageal cancer (ESC) Gastric cancer (GC) Gastric intestinal metaplasia Premalignant lesion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.